Post by Alvotech

Thank you to Citeline’s Generics Bulletin for highlighting Alvotech’s continued progress in the global biosimilars market and the advancement of our proposed vedolizumab biosimilar programs across both the U.S. and Europe.   With FDA acceptance of our interchangeable vedolizumab filing for the IV formulation and EMA validation of our vedolizumab filing covering both IV and subcutaneous formulations, we have reached another important milestone in advancing our biosimilars portfolio and building momentum for the next phase of growth.   Read the article by Dean Rudge on Citeline here: https://lnkd.in/ev8VTeXH